Earnings Call · Q4 FY2025·2026-03-24

Q2 21EPS n/a·Rev n/aQ1 21EPS n/a·Rev n/aQ4 20EPS n/a·Rev n/aQ2 20EPS n/a·Rev n/a⚠ consensus missing

NRX Pharmaceuticals, Inc. NRXPW

Michael Abrams — Chief Financial Officer

Jonathan Javitt — Chief Executive Officer

−23.6%1d on move date−24.9% vs SPY3d−24.6%5d−26.1%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NRXPW calls or request research access.

More NRXPW calls Browse calls Request research access